A clinical study highlighted risks of underestimating atherosclerosis' early markers.
About 69% of the apparently healthy and asymptomatic middle-aged participants presented in fact endothelial dysfunctions (FMD) and about 33% altered levels of circulating oxidized LDL cholesterol (cLDLox).
Both are key biomarkers of atherosclerosis development, progression and complications. In this study the protective properties of polyphenols (Pomanox®, Mediteanox®) were also tested.
Improving endothelial functions and lowering cLDLox significantly restored healthy cardiovascular values, contributing to cardiovascular risk reduction.